400 related articles for article (PubMed ID: 27600150)
21. [Pharmacological treatment in adrenal Cushing's syndrome.].
Stigliano A; Cerquetti L; Toscano V
Recenti Prog Med; 2016 Nov; 107(11):574-581. PubMed ID: 27869874
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Fleseriu M; Pivonello R; Elenkova A; Salvatori R; Auchus RJ; Feelders RA; Geer EB; Greenman Y; Witek P; Cohen F; Biller BMK
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):855-865. PubMed ID: 31542384
[TBL] [Abstract][Full Text] [Related]
23. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
24. Osilodrostat oral tablets for adults with Cushing's disease.
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Rev Endocrinol Metab; 2022 Mar; 17(2):99-109. PubMed ID: 35220871
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological treatment of hypercortisolism.
Shalet S; Mukherjee A
Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):234-8. PubMed ID: 18438170
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of pharmacological options for Cushing's disease: what are the state-of-the-art options?
Martino M; Aboud N; Lucchetti B; Salvio G; Arnaldi G
Expert Opin Pharmacother; 2023 Apr; 24(5):557-576. PubMed ID: 36927238
[TBL] [Abstract][Full Text] [Related]
27. Cushing's disease: role of preoperative and primary medical therapy.
Castinetti F
Pituitary; 2022 Oct; 25(5):737-739. PubMed ID: 35780261
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of Metyrapone in Treating Cushing's Syndrome: A Retrospective Multicenter Study in 195 Patients.
Daniel E; Aylwin S; Mustafa O; Ball S; Munir A; Boelaert K; Chortis V; Cuthbertson DJ; Daousi C; Rajeev SP; Davis J; Cheer K; Drake W; Gunganah K; Grossman A; Gurnell M; Powlson AS; Karavitaki N; Huguet I; Kearney T; Mohit K; Meeran K; Hill N; Rees A; Lansdown AJ; Trainer PJ; Minder AE; Newell-Price J
J Clin Endocrinol Metab; 2015 Nov; 100(11):4146-54. PubMed ID: 26353009
[TBL] [Abstract][Full Text] [Related]
29. New and emerging drug therapies for Cushing's disease.
Störmann S; Schopohl J
Expert Opin Pharmacother; 2018 Aug; 19(11):1187-1200. PubMed ID: 30048162
[TBL] [Abstract][Full Text] [Related]
30. Metyrapone Versus Osilodrostat in the Short-Term Therapy of Endogenous Cushing's Syndrome: Results From a Single Center Cohort Study.
Detomas M; Altieri B; Deutschbein T; Fassnacht M; Dischinger U
Front Endocrinol (Lausanne); 2022; 13():903545. PubMed ID: 35769081
[TBL] [Abstract][Full Text] [Related]
31. Update on medical treatment for Cushing's disease.
Cuevas-Ramos D; Lim DST; Fleseriu M
Clin Diabetes Endocrinol; 2016; 2():16. PubMed ID: 28702250
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological therapy of Cushing's syndrome: drugs and indications.
Díez JJ; Iglesias P
Mini Rev Med Chem; 2007 May; 7(5):467-80. PubMed ID: 17504182
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11β-hydroxylase inhibitor, in Japanese patients with endogenous Cushing's syndrome other than Cushing's disease.
Tanaka T; Satoh F; Ujihara M; Midorikawa S; Kaneko T; Takeda T; Suzuki A; Sato M; Shimatsu A
Endocr J; 2020 Aug; 67(8):841-852. PubMed ID: 32378529
[TBL] [Abstract][Full Text] [Related]
34. Management and Medical Therapy of Mild Hypercortisolism.
Favero V; Cremaschi A; Falchetti A; Gaudio A; Gennari L; Scillitani A; Vescini F; Morelli V; Aresta C; Chiodini I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768949
[TBL] [Abstract][Full Text] [Related]
35. Medical therapy for Cushing's disease: adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers.
Fleseriu M; Petersenn S
Pituitary; 2015 Apr; 18(2):245-52. PubMed ID: 25560275
[TBL] [Abstract][Full Text] [Related]
36. Mifepristone (RU 486) in Cushing's syndrome.
Johanssen S; Allolio B
Eur J Endocrinol; 2007 Nov; 157(5):561-9. PubMed ID: 17984235
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Cushing's disease: a mechanistic update.
Cuevas-Ramos D; Fleseriu M
J Endocrinol; 2014 Nov; 223(2):R19-39. PubMed ID: 25134660
[TBL] [Abstract][Full Text] [Related]
38. Cushing's syndrome: a combined treatment with etomidate and osilodrostat in severe life-threatening hypercortisolemia.
Dzialach L; Sobolewska J; Respondek W; Wojciechowska-Luzniak A; Witek P
Hormones (Athens); 2022 Dec; 21(4):735-742. PubMed ID: 36129663
[TBL] [Abstract][Full Text] [Related]
39. Cushing's syndrome: an update on current pharmacotherapy and future directions.
Creemers SG; Hofland LJ; Lamberts SW; Feelders RA
Expert Opin Pharmacother; 2015; 16(12):1829-44. PubMed ID: 26133755
[TBL] [Abstract][Full Text] [Related]
40. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism.
Ferriere A; Salenave S; Puerto M; Young J; Tabarin A
Eur J Endocrinol; 2024 Jan; 190(1):L1-L3. PubMed ID: 38123490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
